Kura Oncology, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On November 3, 2025, we announced receipt of a $30.0 million milestone payment under the Kyowa License Agreement in connection with the dosing of the first patient in the second of two KOMET-017 Phase 3 registrational trials of ziftomenib.
Trading Plans
During the three months ended September 30, 2025, certain of our directors and officers adopted, modified or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Trading Arrangement | |||||
|---|---|---|---|---|---|
| Name and Position · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares to be Sold · Expiration Date | |||||
| Kathleen Ford, Chief Operating Officer | Termination*** | August 28, 2025 | X | 74,438, and ESPP net shares to be purchased | September 15, 2025 |
| Kathleen Ford, Chief Operating Officer | Adoption*** | August 29, 2025 | X | 79,696, PSUs and RSUs net shares to be received, and ESPP net shares to be purchased | August 31, 2026 |
| Teresa Bair, Chief Legal Officer | Adoption | September 4, 2025 | X | 218,021, and ESPP net shares to be purchased | December 5, 2026 |
| Mollie Leoni, M.D., Chief Medical Officer | Adoption | September 9, 2025 | X | 99,531, and RSUs net shares to be received | December 31, 2026 |
| Brian Powl, Chief Commercial Officer | Adoption | September 19, 2025 | X | 90,116, Options net shares unsold, RSUs net shares to be received, and ESPP net shares to be purchased | December 31, 2026 |
| Faheem Hasnain, Lead Independent Director | Adoption | September 9, 2025 | X | 20,000 | June 9, 2027 |
- Intended to satisfy the affirmative defense of Rule 10b5-1(c)
** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)
*** Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written plan adopted on June 10, 2024 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
In addition, our officers (as defined in Rule 16a-1(f) under the Exchange Act) have entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy our tax withholding obligations arising exclusively from the vesting of shares of restricted stock. The amount of shares to be sold to satisfy our tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of our shares. The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vesting date of the applicable shares of restricted stock and the officer’s termination of service.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.